At around 8 o'clock today, the 2026 national basic medical insurance drug catalogue negotiations and the fifth day of commercial insurance innovative drug catalogue price negotiations officially began. The reporter learned on the spot that today is the last day of this year's national talks. Intensive negotiations on commercial insurance innovative drug catalogue prices will be carried out. The basic medical insurance catalogue negotiations were completed yesterday morning. Representatives from companies such as AstraZeneca, Sanofi, Keji Pharmaceutical's subsidiary Kaixing Life, Yuanda, Hengrun Dasheng, and Precision Biology entered the negotiation venue one after another. A total of 62 generic drug names were declared in the commercial insurance innovative drug catalogue price negotiations this year. Of these, 57 were outside the catalogue and 1 in the catalogue. Rare diseases, tumors, and neurological diseases were still the main reporting forces, accounting for about 70% of the total. Hengrun Dasen's Reniche Orense injection and Precise Biologices' Prichiolensis injection, two new CAR-T drugs tried to “break through” for the first time.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.